Drug intelligence / Profile preview

CD74 siRNA

Development stage
Preclinical
Lead developer
University of Texas MD Anderson Cancer Center
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

CD74 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the CD74 gene, which encodes the HLA class II-associated invariant chain. CD74 is a multifunctional protein that serves as a chaperone for MHC class II molecules and as a cell-surface receptor for macrophage migration inhibitory factor (MIF). Overexpression of CD74 is associated with various malignancies, including metastatic melanoma, where it promotes cell proliferation and survival. By targeting CD74 mRNA for degradation via the RNA interference (RNAi) pathway, CD74 siRNA reduces CD74 protein levels, leading to the inhibition of tumor cell growth. Preclinical studies, such as those conducted at the UT M.D. Anderson Cancer Center, have identified CD74 as a viable therapeutic target for the treatment of advanced melanoma.

Other names
siRNA targeting CD74CD74-specific siRNACD-74-specific siRNACD 74-specific siRNA
02

Targets

CD74 (Major histocompatibility complex class II invariant chain)

Beyond the preview

Go deeper on CD74 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD74 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call